Polyendocrine Metabolic Syndrome (PMOS), formerly PCOS, is the most common hormonal and metabolic disorder in women of reproductive age, affecting up to 13% and contributing to nearly 40% of infertility cases. FAU researchers reviewed more than 2,200 studies and identified 29 focusing on non-pharmacological care in midlife and reproductive aging. Findings of the analysis show lifestyle interventions – especially diet and exercise –are most consistently supported, while evidence for complementary therapies is limited and chronic pain and mental health remain largely understudied.

The intravenous infusion of mesenchymal stem cells from family donors is safe and improves symptoms such as pruritus (itching), sleep disturbances, and fatigue associated with Recessive Dystrophic Epidermolysis Bullosa (RDEB), popularly known as "butterfly skin". This is one of the primary conclusions of a clinical trial conducted by researchers from the Universidad Carlos III de Madrid (UC3M), the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) of the Ministry of Science, Innovation and Universities, the Fundación Jiménez Díaz Health Research Institute (IIS-FJD), the CIBER Rare Diseases (CIBERER), and the La Paz University Hospital in Madrid.

A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference. The drug, called AD109, is the first therapy to treat OSA by addressing its underlying mechanisms and targeting the neuromuscular causes of airway collapse. “Aroxybutynin and Atomoxetine (AD109) for Obstructive Sleep Apnea: A Randomized Phase 3 Trial” will be published in the American Journal of Respiratory and Critical Care Medicine.